Overview

CytoSorbents Investor Relations

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with >270,000 CytoSorb devices sold in 70+ countries to date, and with applications to FDA and Health Canada for DrugSorb-ATR marketing approval under review.

Featured News

CytoSorbents

Press Release

20 Aug '25

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., Aug. 20, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, ... CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

07 Aug '25

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

PRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2025, and recent business highlights. Second Quarter 2025 Financial Results Revenue was $9.6 million, an ... CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

31 Jul '25

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th PRINCETON, N.J., July 31, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ... CytoSorbents Leads a New Era in Sepsis Treatment

29 Jul '25

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

PRINCETON, N.J., July 29, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2025 financial results and recent business highlights after the market close on Thursday, August 7, 2025. CytoSorbents’ management will host a ... CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

View All News